Clinical Performance Evaluation of a SARS-CoV-2 Rapid Antibody Test for Determining Past

Exposure to SARS-CoV-2

Peter Findeisen[a], Hugo Stiegler[b], Eloisa Lopez-Calle[c], Tanja Schneider[d], Eva Urlaub[c], Johannes

Hayer[c], Claudia Zemmrich[e,f#]

[a]MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg, Germany

[b]MVZLM - Medizinisches Versorgungszentrum für Labormedizin und Mikrobiologie Ruhr GmbH,

45138 Essen, Germany

[c]Roche Diagnostics GmbH, Mannheim, Germany

[d]Roche Diagnostics GmbH, Penzberg, Germany

[e#]Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831 Mahlow,

Germany

[f]Roche Diagnostics International Ltd. Rotkreuz, Switzerland

Corresponding author: Claudia Zemmrich, Institute for Pharmacology and Preventive Medicine,

Menzelstrasse 21, 15831 Mahlow, Germany, claudia.zemmrich@ippmed.de

Running title: Performance of a SARS-CoV-2 rapid antibody test

Target: Journal of Clinical Microbiology

Abstract

The true prevalence and population seropositivity of SARS-CoV-2 infection remains unknown,

due to the number of asymptomatic infections and limited access to high-performance

antibody tests. To control the COVID-19 pandemic it is crucial to understand the true

seroprevalence, but not every region has access to extensive centralized PCR and serology

testing. Currently available rapid antibody tests lack the accuracy needed for recommendation

by health authorities. To fill this gap, we analyzed and validated the clinical performance of a

new point-of-care SARS-CoV-2 Rapid Antibody Assay, a chromatographic immunoassay for

qualitative detection of IgM/IgG antibodies for use in near-patient settings. Analysis was

performed using 42 Anti-SARS-Cov-2 positive (CoV+) and 92 Anti-SARS-Covid-2 negative (CoV-)

leftover samples from before December 2019, using the Elecsys® Anti-SARS-CoV-2 as the

reference assay. Analytical specificity was tested using leftover samples from individuals with

symptoms of common cold collected before December 2019. The SARS-CoV-2 Rapid Antibody

Test was 100.0% (95% CI 91.59–100.00) sensitive and 96.74% (95% CI 90.77–99.32) specific with

an assay failure rate of 0.00%. No cross-reactivity was observed against the common cold panel.

Method comparison was additionally conducted by two external laboratories, using 100

CoV+/275 CoV- samples, also comparing whole blood versus plasma matrix. The comparison

demonstrated for plasma 96.00% positive/96.36% negative percent agreement with the Elecsys

Anti-SARS-CoV-2 and overall 99.20% percent agreement between whole blood and EDTA

plasma. The SARS-CoV-2 Rapid Antibody Test demonstrated similar clinical performance to the

manufacturer's data and to a centralized automated immunoassay, with no cross-reactivity to

common cold panels.

Key words: SARS-CoV-2, rapid antibody test, past exposure

Introduction

The global COVID-19 pandemic created an urgent unmet clinical need to investigate reliable

diagnostic tools for patients, as well as understand the extent of exposure and spread of

infection among wider populations (1-3). Acute diagnosis of the COVID-19 infection is based on

identification of viral RNA via PCR from swab samples, which is detectable from symptom onset

for approximately four weeks (2, 4). As is known from localized testing during outbreaks, many

people who are infected with the virus do not present with any clinical symptoms – current

estimates suggest around 30% of seropositive individuals are asymptomatic (5-7). Those

individuals carry the virus and potentially spread it to others, who may react with a severe

COVID-19 disease (8). No region in the world can perform PCR testing of every patient with

common cold symptoms or who has had contact with a suspected COVID-19 patient. In addition

to clinical testing of individuals with suspected COVID-19 for direct virus detection, surveillance

strategies need to combine several diagnostic techniques to monitor disease kinetics in wider

populations (2, 9). To control the pandemic, it seems crucial to investigate who has already had

an infection and has developed antibodies as an immune response, and vice versa, who is still

vulnerable to an infection (10-14).

Antibody tests are not intended to diagnose an acute COVID-19 infection, more specific

diagnostic methods should be performed to obtain this (2). Ongoing research on the level and

duration of immunity of seropositive persons will add further value to the clinical and

epidemiological interpretation of positive antibody testing results. Preliminary data suggest

that high affinity antibody tests show good correlation with neutralizing activity (15).

Based on current evidence, immunoglobulin M (IgM) antibodies are detectable within 5 days

after symptom onset and immunoglobulin G (IgG) antibodies within 5–7 days (4, 16-23).

Depending on the applied method, seroconversion is observed after a median of 10–13 days

after symptom onset for IgM and 12–14 days for IgG, and maximum for both is reached after 2

weeks (4, 16, 19-26). Individual levels and kinetics of both IgM and IgG are highly variable,

which is why simultaneous detection of both is recommended.

Currently available rapid antibody tests require improved accuracy before being recommended

by competent authorities and used by healthcare professionals (HCPs) in the wider population

(2, 3). The US Food and Drug Administration (FDA) released technical requirements for antibody

tests on April 4, 2020, that include a specificity of ≥ 95% and cross-reactivity testing for

common cold and other coronaviruses (27). There are different high-throughput Anti-SARS-

CoV-2 antibody tests available; the assay selected as the reference for our test (Elecsys Anti-

SARS-CoV-2 Immunoassay) is based on electrochemiluminescence (ECLIA), using a double-

antigen sandwich test principle and a recombinant protein representing the antigen for the

determination of antibodies to SARS-CoV-2, namely the nucleocapsid protein (N) (28). It

provides a qualitative result with a sensitivity of 100.0% (95% CI 88.10–100.0) at ≥ 14 days after

PCR confirmation and a specificity of 99.81% (95% CI 99.65–99.91) (28).

Rapid tests, also called point-of-care (PoC) tests, combine immunoassay and chromatography

for a qualitative detection of antibodies. The selected test *(Anti-SARS-CoV-2 Rapid Antibody*

Test [SD Biosensor, Chungcheongbuk-do, Republic of Korea]) is a CE marked lateral flow assay

displaying a visual 'yes/no' answer for the selective detection of specific IgG and/or IgM

antibodies to SARS-CoV-2, with two separate colored bands for IgG and IgM (29). The

manufacturer states the specificity is 98.65% and sensitivity beyond 14 days after symptom

onset of 99.03%, tested on 103 PCR-confirmed CoV+ and 222 CoV- samples (29). The samples

had also been tested for early sensitivity between 7 and 14 days after symptom onset with a

result of 92.59%. SD Biosensor has performed several cross-reactivity studies involving

numerous specimens, including influenza A and B.

In this study series, we further validated and extended the manufacturers' clinical performance

and cross-reactivity data and externally performed a matrix and method comparison to gain

additional data on the overall assay performance.

Materials and Methods

The assay

The assay *(Figure 1)* needs 10 µl human serum or plasma, or 20 µl whole venous or capillary

blood sample to be filled into the preformed well of the test device. Three pre-coated lines

mark the "C" control line, and the "G" and "M" test lines for IgG and IgM. Monoclonal chicken

IgY antibody is coated on the "C" region, and monoclonal anti-human IgG antibody and

monoclonal anti-human IgM antibody are coated on the "G" and "M" test line region. During

the test, SARS-CoV-2-specific antibodies in the sample interact with recombinant SARS-CoV-2

protein (nucleocapsid and spike protein) conjugated with colloidal gold particles forming

antibody–antigen gold particle complexes. This complex migrates on the membrane via

capillary action until the "M" and "G" test line, where it will be captured by the monoclonal

anti-human IgG antibody or monoclonal anti-human IgM antibody. A violet test line would be

visible in the result window if SARS-CoV-2-specific antibodies are present in the sample. The

intensity of the colored test line varies depending upon the amount of SARS-CoV-2 antibodies

present in the sample. Even if the color is faint, the test result should be interpreted as a

positive result. The control line is used as procedural control and should always appear if the

test procedure is performed properly and the test reagents are working.

Study design

A performance analysis was conducted at Roche Diagnostics (Penzberg, Mannheim, Germany)

using 42 Elecsys Anti-SARS-CoV-2 confirmed CoV+ and 92 leftover samples from healthy donors,

collected before December 2019 and additionally confirmed by the Elecsys Anti-SARS-CoV-2

CoV- (56 lithium heparin plasma, 36 EDTA plasma). Cross-reactivity testing was conducted with

18 samples from individuals expressing signs and symptoms of common cold (i.e. sore throat,

cough, fever) collected before December 2019. Additional matrix equivalence and read-out

time analysis captured 159 Elecsys referenced CoV- samples, consisting of 55 heparin plasma,

55 EDTA plasma and 49 serum samples.

Additionally, an independent comparison was performed with matched EDTA plasma and

whole blood samples from a total of 375 anonymized leftover samples at two external testing

sites. In total, 100 samples tested positive for SARS-CoV-2 antibodies by the Elecsys anti–SARS-

CoV2 immunoassay and 275 negative samples from before December 2019 and additionally

tested negative (25 CoV+/75 negative- subjects at MVZLM Ruhr GmbH, Essen and 75 CoV+/200

negative subjects at MVZ Labor Dr. Limbach & Kollegen GbR Heidelberg). No information on

PCR result or time of sample collection related to symptom onset was available. All samples

were analyzed with the Anti-SARS-CoV-2 Rapid Antibody Assay and results were compared

directly with the EDTA plasma sample from the Elecsys Anti-SARS-CoV-2 Assay (see Figure 1 for

workflow).

All investigations were performed according in a single determination and according to the

manufacturer's instructions for use.

Statistical analyses

For sensitivity and specificity, point estimates and 95% CI values were calculated. To determine

positive and negative percent agreement (PPA and NPA), the Elecsys Anti-SARS-CoV-2 result

was used as comparator: »Non-reactive« (cut off index [COI] < 1.0) was a negative result and

»Reactive« (COI ≥ 1.0) a positive result. The rapid test was considered positive in case either IgG

or IgM showed a colored line, even if the line was faint. The Clopper–Pearson exact method

was used for the calculation of the two-sided 95% confidence intervals (CIs).

Ethics and conformity declaration

The study was conducted in accordance with applicable regulations, including relevant

European Union directives and regulations, and the principles of the Declaration of Helsinki. All

samples were anonymized leftover specimens. For the samples tested at Roche Diagnostics, a

statement was obtained from the Ethics Committee of the Landesärztekammer Bayern

confirming that there are no objections against the transfer and the coherent use of the

anonymized leftover samples. For the samples tested in MVZLM Ruhr GmbH (Essen) and at

MVZ Labor Dr. Limbach & Kollegen GbR (Heidelberg) no ethics committee vote is required in

accordance with MPG (Medizinproduktegesetz Deutschland).

Data availability

Qualified researchers may request access to individual patient level data through the clinical

study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible

studies are available here: https://vivli.org/members/ourmembers/. For further details on

Roche's Global Policy on the Sharing of Clinical Information and how to request access to

related clinical study documents, see here:

https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_tria

ls/our_commitment_to_data_sharing.htm.

Results

Clinical performance evaluation

The assay presented a qualitative visual test result without the need for a read-out instrument

like other rapid antibody devices on the market. Some lines were quite faint, and according to

manufacturer's instruction they have been interpreted as a positive result. Handling was easy

with one sample-transfer step and three drops of buffer dropped into the well after the blood

sample; the results read at 10–15 minutes. Except quality control material, lancets and a

transferring pipette for 10 µl, everything needed to conduct the test was included into the test

package. All test cassettes were correctly assembled, opening the foil pouch was easy without

danger of destroying the desiccant and no membranes were scratched.

A total of 42 left-over samples with prior Elecsys-confirmed positive SARS-CoV-2 antibody

detection were included in the sensitivity analysis. The overall sensitivity was 100.0% (95 % CI

91.59–100.0) (Table 1). A total of 92 samples from healthy donors before December 2019

presented an overall specificity of 96.74% (95% CI 90.77–99.32) with no difference between

EDTA and lithium-heparin plasma: 97.22% (95% CI: 85.47–99.93)/96.43% (95% CI 87.69–99.56).

An additional matrix evaluation and read-out time analysis was performed with 159 SARS-CoV-2

negative samples to confirm equal results throughout the pre-defined read-out time window.

At read out times ≤10 minutes specificity was slightly higher versus at 15 minutes (Table 2),

however detectable signals were 'weaker' or less well defined at ≤10 minutes compared with

15 minutes read out time. No relevant performance differences were noticed between serum,

heparin and EDTA plasma (Table 2).

Cross-reactivity was tested at 18 samples from a common cold panel, collected before

December 2019 without further information on the exact pathogens of the specimens. For all

18 measurements, a colored control line was obtained, indicating that the test worked

properly. On the test lines for IgG and IgM no color appeared, thus leading to a negative result

and resulting in a specificity of 100.0% (95 % CI 81.47–100.0%). The results demonstrated that

the test is not reacting with antibodies directed against related pathogens from common cold

infections.

External method and matrix comparison

Total results for both testing methods (plasma/whole blood samples) were 96.00% (95 % CI

90.07–98.90) / 94.00% (95% CI 87.40–97.77) for positive percent agreement rate and 96.36%

(95% CI 93.41–98.24) / 96.00 % (95% CI 92.96–97.99) for negative percent agreement rate. The

sample numbers per matrix and per immunoglobulin class for the samples confirmed by the

Elecsys test and the numbers differing from the Elecsys result are summarized in Table 3. The

overall percent agreement rate between whole blood and EDTA plasma was 99.20% (95% CI

97.68–99.83), the positive/negative percent agreement rates for whole blood versus EDTA

plasma were 98.11 % (95% CI 93.35–99.77) / 99.63 (95% CI 97.95–99.99).

A total of 10 EDTA samples and 11 whole blood samples were detected antibody positive by the

Anti-SARS-CoV-2 Rapid Antibody Assay but antibody negative by the Elecsys assay, see Table 4a

for the respectively detected immunoglobulin classes and the respective signal intensity on the

11 rapid tests. 96 plasma and 94 whole blood samples out of 100 Elecsys-positive samples were

detected positive by the rapid test, see Table 4b for the respective immunoglobulin classes and

signal intensity of the six rapid test results. The matrix comparison for the Anti-SARS-CoV-2

Rapid Antibody Assay found of 106 plasma samples with an antibody positive test result,

included two samples which had negative tests results with whole blood. One out of 269

negative test results on the rapid test with plasma displayed a positive result with whole blood.

Discussion

The COVID-19 pandemic has created an urgent need for antibody testing of large populations to

determine seroprevalence and potential immunity, which will be of more importance if more

conclusive scientific data on correlation between these factors become available (2, 3, 26, 30,

31). The anticipated need for high testing capacities in PoC settings outside of large hospitals,

calls for the development and validation of high-performance rapid antibody tests as reliable

diagnostic instruments, in addition to the centralized antibody tests available. The evaluated

Anti-SARS-CoV-2 Rapid Antibody Test complies with the acceptance criteria, defined by the FDA

EUA on April 4, 2020, for SARS-CoV-2 antibody test developments (27). Our internal clinical

performance evaluation confirmed the manufacturers' reported clinical sensitivity of the test

with an uncharacterized cohort of antibody positive samples from a population with unknown

time from symptom onset, which may reflect the typical clinical scenario for the test indication.

The external comparison confirmed high agreement of both the Elecsys assay and the Anti-

SARS-CoV-2 Rapid Antibody Test, also with no confirmed PCR result and time of sampling from

symptom onset unknown. For both the internal and external evaluation, samples could be

mixed, with some collected early after symptom onset. Both tests claim less than 100 %

sensitivity <14 days after symptom onset (28, 29). The Elecsys Anti-SARS-CoV-2 Antibody Test

measures high-affinity IgG/IgM antibodies directed at the nucleocapsid antigen, with an

excellent sensitivity of 100.0% (95% CI 88.1–100.0) at ≥ 14 days after PCR confirmation (28). The

rapid test has been developed detecting both nucleocapsid- and spike protein-associated

antibodies to increase test accuracy compared with centralized serological assays, which

typically perform better than rapid tests. (29). A limitation of this study is that samples were

not differentiated according to time of collection after symptom onset, as such some of the

false positive samples might actually be true positives, but were not detected by the Elecsys

assay and most likely indicate an early antibody response with low affinity antibodies. For SARS-

CoV-2 tests high specificity is a priority, particularly in low prevalence settings (30), as such it

would be interesting to further evaluate the interpretation of the low positive samples at the

rapid test, particularly for samples that were IgM positive only, to determine if these reflect

non-specific binding, or true early detection. Further assessment with serial samples taken from

COVID-19 patients from early infection phase onwards will help to better understand this.

The investigated Anti-SARS-CoV-2 Rapid Antibody Test provided readily evaluable results,

regardless of sample type (whole blood or EDTA plasma) and independent of any read-out time

between 10 and 15 minutes, as stated in the instructions for use. Those positive practical

aspects could enable potential use outside medical environments. The assay is currently

intended for professional use in laboratory and PoC environments as an aid in identifying

individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection.

In these studies, the SARS-CoV-2 Rapid Antibody Test demonstrates excellent clinical

performance without cross-reactivity to common cold samples and results comparable to data

of an automated high-performance immunoassay (Elecsys). Our data confirm and extend the

manufacturers' performance data and add further details on matrix and method comparisons.

Available data support its use as a reliable diagnostic instrument for SARS-CoV-2 IgM and IgG

antibody detection in near-patient settings with potential extended usability outside medical

environments.

Acknowledgements

The authors would like to acknowledge the contributions of Rabea Held, Regina Draude,

Marcus Pollok (Roche Diagnostics GmbH, Mannheim, Germany) for testing, data acquisition in

the laboratory and preliminary data analysis. In addition, thanks to Imola Szebenyi, Oscar

Gutierrez-Sanz, Miriam Hübner, Ludwig Pollich, Nicolai Bluthardt, Andreas Aristow (Roche

Diagnostics GmbH, Penzberg, Germany) for the measurements of the clinical and cross-

reactivity samples as part of the study conducted at Roche Diagnostics. Thanks to John Burden

(Roche Diagnostics International Ltd. Rotkreuz, Switzerland), Sven Groesgen (Roche Diagnostics

GmbH, Mannheim, Germany) and Christine Jung (Roche Diagnostics GmbH, Penzberg,

Germany) for planning, set-up and analysis of the external evaluation. The authors would also

like to acknowledge Matthias Metz and Daria Glukhova for conducting the measurements with

the Elecsys SARS-CoV-2 method as part of the study at Roche Diagnostics.

Conflicts of interest/financial disclosures

Eloisa Lopez-Calle, Tanja Schneider, Eva Urlaub, Johannes Hayer, are all employees of Roche

Diagnostics. Claudia Zemmrich works as a freelance contractor for Roche Diagnostics.

References

1. The World Health Organization. 2020. Immunity passports in the context of COVID-19.

https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-

covid-19. Accessed July 2020.

2. The European Centre for Disease Prevention and Control. 2020. Diagnostic testing and

screening for SARS-CoV-2. https://www.ecdc.europa.eu/en/covid-19/latest-

evidence/diagnostic-testing. Accessed July 2020.

3. The US Centers for Disease Prevention and Control. 2020. Interim guidelines for COVID-19

antibody testing. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-

guidelines.html. Accessed June 2020.

4. Sethuraman N, Jeremiah SS, Ryo A. 2020. Interpreting diagnostic tests for SARS-CoV-2. JAMA

doi:10.1001/jama.2020.8259.

5. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda M, Sanmartin JL,

Fernandez-Garcia A, Cruz I, Fernandez de Larrea N, Molina M, Rodriguez-Cabrera F, Martin M,

Merino-Amador P, Leon Paniagua J, Munoz-Montalvo JF, Blanco F, Yotti R, Group E-CS. 2020.

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based

seroepidemiological study. Lancet doi:10.1016/S0140-6736(20)31483-5.

6. Sandri MT, Azzolini E, Torri V, Carloni S, Tedeschi M, Castoldi M, Mantovani A, Rescigno M. 2020.

IgG serology in health care and administrative staff populations from 7 hospital representative

of different exposures to SARS-CoV-2 in Lombardy, Italy. medRxiv

doi:10.1101/2020.05.24.20111245:2020.05.24.20111245.

7. Mizumoto K, Kagaya K, Zarebski A, Chowell G. 2020. Estimating the asymptomatic proportion of

coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship,

Yokohama, Japan, 2020. Euro Surveill 25;(10):2000180

8.   European Centre for Disease Prevention and Control. 2020. Transmission of COVID-19.

https://www.ecdc.europa.eu/en/covid-19/latest-evidence/transmission. Accessed July 2020.

9.   The World Health Organization. 2020. Surveillance strategies for COVID-19 human infection:

interim guidance. https://www.who.int/publications/i/item/surveillance-strategies-for-covid-19-

human-infection. Accessed July 2020.

10.   Althoff KN, Coburn SB, Nash D. 2020. Contact tracing: Essential to the public health response

and our understanding of the epidemiology of COVID-19. Clin Infect Dis

doi:10.1093/cid/ciaa757.

11.   Fiore VG, DeFelice N, Glicksberg BS, Perl O, Shuster A, Kulkarni K, O'Brien M, Pisauro MA, Chung

D, Gu X. 2020. Containment of future waves of COVID-19: simulating the impact of different

policies and testing capacities for contact tracing, testing, and isolation. medRxiv

doi:10.1101/2020.06.05.20123372.

12.   MacIntyre CR. 2020. Case isolation, contact tracing, and physical distancing are pillars of COVID-

19 pandemic control, not optional choices. Lancet Infect Dis doi:10.1016/S1473-3099(20)30512-

0.

13.   Sen-Crowe B, McKenney M, Elkbuli A. 2020. COVID-19 laboratory testing issues and capacities as

we transition to surveillance testing and contact tracing. Am J Emerg Med

doi:10.1016/j.ajem.2020.05.071.

14.   Steinbrook R. 2020. Contact Tracing, Testing, and Control of COVID-19-Learning From Taiwan.

JAMA Intern Med doi:10.1001/jamainternmed.2020.2072.

15.   Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y,

Huang J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient

cohort and their implications. medRxiv

doi:10.1101/2020.03.30.20047365:2020.03.30.20047365.

16.   Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L,

Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. 2020. Profiling early

humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis

doi:10.1093/cid/ciaa310.

17. Liu L, Liu W, Wang S, Zheng S. 2020. A preliminary study on serological assay for severe acute

respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. medRxiv

doi:10.1101/2020.03.06.20031856:2020.03.06.20031856.

18. Long Q-X, Deng H-J, Chen J, Hu J, Liu B-Z, Liao P, Lin Y, Yu L-H, Mo Z, Xu Y-Y, Gong F, Wu G-C,

Zhang X-C, Chen Y-K, Li Z-J, Wang K, Zhang X-L, Tian W-G, Niu C-C, Yang Q-J, Xiang J-L, Du H-X, Liu

H-W, Lang C, Luo X-H, Wu S-B, Cui X-P, Zhou Z, Wang J, Xue C-J, Li X-F, Wang L, Tang X-J, Zhang Y,

Qiu J-F, Liu X-M, Li JJ, Zhang D-C, Zhang F, Cai X-F, Wang D, Hu Y, Ren J-H, Tang N, Liu P, Li Q,

Huang A-L. 2020. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective

application of serological tests in clinical practice. medRxiv

doi:10.1101/2020.03.18.20038018:2020.03.18.20038018.

19. Lou B, Li T, Zheng S, Su Y, Li Z, Liu W, Yu F, Ge S, Zou Q, Yuan Q, Lin S, Hong C, Yao X, Zhang X, Wu

D, Zhou G, Hou W, Li T, Zhang Y, Zhang S, Fan J, Zhang J, Xia N, Chen Y. 2020. Serology

characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv

doi:10.1101/2020.03.23.20041707:2020.03.23.20041707.

20. Okba NMA, Marcel AM, Wentao L, Chunyan W, Corine HG, Victor MC, Mart ML, Reina SS, Erwin

de B, Felicity DC, Yazdan Y, Quentin Le H, Diane D, Nadhira H-F, Chantal BEMR, Berend-Jan B,

Christian D, Marion PGK, Bart LH. 2020. Severe acute respiratory syndrome coronavirus

2–Specific antibody responses in coronavirus disease 2019 patients. Emerging Infectious Disease

journal 26(7):1478–88..

21. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, He X, Qian C, Sun Q, Hu Q, Liu H, Ye S, Xiang X, Zhou

Y, Zhang W, Guo Y, Wang X-H, He W, Wan X, Sun F, Wei Q, Chen C, Pan G, Xia J, Mao Q, Chen Y,

Deng G. 2020. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv

doi:10.1101/2020.03.24.20042382:2020.03.24.20042382.

22. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P, Chan JM-C, Chik

TS-H, Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip JD, Ng AC-K, Poon RW-S, Luo C-T,

Cheng VC-C, Chan JF-W, Hung IF-N, Chen Z, Chen H, Yuen K-Y. 2020. Temporal profiles of viral

load in posterior oropharyngeal saliva samples and serum antibody responses during infection

by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases 20:565-574.

23. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu

Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. 2020. Antibody

responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis

doi:10.1093/cid/ciaa344.

24. Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M, Jiang K, Asthagiri-

Arunkumar G, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L,

Fierer D, Lugo LA, Milunka Kojic E, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL,

Caplivski D, Garcia-Sastre A, Cheng A, Kedzierska K, Vapalahti O, Hepojoki J, Simon V, Krammer

F, Moran T. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv

doi:10.1101/2020.03.17.20037713:2020.03.17.20037713.

25. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, Zhou Q, Ye H, Ma Y, Li H, Wei X, Cai P, Ma WL.

2020. Antibody detection and dynamic characteristics in patients with COVID-19. Clin Infect Dis

doi:10.1093/cid/ciaa461.

26. Zhang J, Liu J, Li N, Liu Y, Ye R, Qin X, Zheng R. 2020. Serological detection of 2019-nCoV respond

to the epidemic: A useful complement to nucleic acid testing. medRxiv

doi:10.1101/2020.03.04.20030916:2020.03.04.20030916.

27. Administration UFaD. 2020. Policy for coronavirus disease-2019 tests during the public health

emergency (Revised). https://www.fda.gov/regulatory-information/search-fda-guidance-

documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised.

28. Roche Diagnostics GmbH. 2020. Elecsys Anti-SARS-CoV-2 Method Sheet.

29. SD Biosensor. 2020. SARS-CoV-2 Rapid Antibody Test Method Sheet.

30. Ozcurumez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M, Neumaier M,

Walter M, Wenzel F, Wolfel R, Renz H, Chemistry C-TFotGSfC, Laboratory M. 2020. SARS-CoV-2

antibody testing-questions to be asked. J Allergy Clin Immunol 146:35-43.

31. Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. 2020. The Role of Antibody

Testing for SARS-CoV-2: Is There One? J Clin Microbiol doi:10.1128/JCM.00797-20.

Table 1. Performance data of the manufacturer, internal clinical performance test, matrix equivalence test and external method comparison

	SD Biosensor data**, % (95% CI)	Internal test, % (95% CI)	Matrix evaluation, % (95% CI)	External comparison (95% CI)
Samples tested, n	195+ / 222-	42+ / 92-	159-	100+ / 275-
Reference method	PCR	Elecsys® Anti-SARS-CoV-2 Antibody Assay	Elecsys® Anti-SARS-CoV-2 Antibody Assay	n.a.
Specificity versus Reference method	98.65 (96.10–99.72)	96.74 (90.77–99.32)	96.23 (91.97–98.60)	96.00*** (90.07–98.90)
Sensitivity versus Reference method • 7–14 days*	92.59 (82.11–97.94)			
• > 14 days*	99.03 (94.71–99.98)			
• All time periods		100 (91.59–100.00)	n.a.	96.36*** (93.41–98.24)

372   n.a. not applicable; +/-, positive/negative for SARS-CoV-2 determined by respective reference method

373   *Post symptom onset; **according to Anti-SARS-CoV-2 Rapid Antibody Assay Method sheet; ***positive/negative percent agreement with

374   Elecsys Anti-SARS-CoV-2 in EDTA plasma, data in italics as generated by comparative analysis, not clinical performance analysis

 Table 2. Matrix evaluation and read-out time analysis

		Read out time			
		8 mins	**10 mins**	**12 mins**	**15 mins**
Total	Number of samples test (negative)	159	159	159	159
	False positive	4	5	6	6
	Specificity % (95% CI)	97.48 (93.68–99.31)	96.86 (92.81–98.97)	96.23 (91.97–98.60)	96.23 (91.97–98.60)
Serum	Number of samples test (negative)	49	49	49	49
	False positive	1	2	2	2
	Specificity % (95% CI)	97.96 (89.15–99.95)	95.92 (86.02–99.50)	95.92 (86.02–99.50)	95.92 (86.02–99.50)
Heparin plasma	Number of samples test (negative)	55	55	55	55
	False positive	1	1	2	2
	Specificity % (95% CI)	98.18 (90.28–99.95)	98.18 (90.28–99.95)	96.36 (87.47–99.56)	96.36 (87.47–99.56)
EDTA plasma	Number of samples test (negative)	55	55	55	55
	False positive	2	2	2	2
	Specificity % (95% CI)	96.36 (87.47–99.56)	96.36 (87.47–99.56)	96.36 (87.47–99.56)	96.36 (87.47–99.56)

7   **Table 3. External comparison to Elecsys Anti-SARS-CoV-2 per matrix and immunoglobulin**

8   **class**

	Number of results (Whole blood)				Number of results (EDTA Plasma)			
	IgM	IgG	IgM+IgG	Total	IgM	IgG	IgM+IgG	Total
SARS-CoV-2 positive (confirmed by Elecsys)	1	57	36	94	0	54	42	96
SARS-CoV-2 negative (confirmed by Elecsys)	0	0	0	264	0	0	0	265
False positive results (compared to Elecsys)	4	5	2	11	3	5	2	10
False negative results (compared to Elecsys)	0	0	0	6	0	0	0	4
OPA (95%CI)	95.47% (92.84–97.34)				96.27% (93.82–97.94)			
PPA (95% CI)	94.00% (87.40–97.77)				96.00% (90.07–98.90)			
NPA (95% CI)	96.00% (92.96–97.99)				96.36% (93.41–98.24)			

9   OPA, overall percentage agreement; PPA, positive percentage agreement; NPA, negative

0   percentage agreement

381   **Table 4a: Method comparison: Discrepant positive samples - detected signal intensity and immunoglobulin class**

Sample number	Rapid AB results – whole blood		Rapid AB results – EDTA plasma		Elecsys results (EDTA plasma)	
	IgG	IgM	IgG	IgM	Result	COI
1	-	X (weak)	-	X (weak)	Non-reactive	0.089
2	-	X (weak)	-	X (weak)	Non-reactive	0.119
3	-	X (weak)	-	X (weak)	Non-reactive	0.089
4	X (weak)	-	X (weak)	-	Non-reactive	0.079
5	-	X (weak)	-	-	Non-reactive	0.069
6	X (weak)	X (weak)	X (weak)	X (weak)	Non-reactive	0.229
7	X	-	X	-	Non-reactive	0.146
8	X (weak)	-	X (weak)	-	Non-reactive	0.221
9	X (weak)	-	X (weak)	-	Non-reactive	0.269
10	X	X	X	X	Non-reactive	0.189
11	X	-	X	-	Non-reactive	0.378

382   AB, antibody

383   **Table 4b Method comparison: Discrepant negative samples - detected signal intensity and immunoglobulin class**

Sample number	Rapid AB results – whole blood		Rapid AB results – EDTA plasma		Elecsys results (EDTA plasma)	
	IgG	IgM	IgG	IgM	Result	COI
1	-	-	-	-	Reactive	1.21
2	-	-	-	-	Reactive	1.99
3	-	-	X (weak)	-	Reactive	39.54
4	-	-	-	-	Reactive	2.32
5	-	-	-	-	Reactive	2.34
6	-	-	X (weak)	-	Reactive	16.7

384   AB, antibody

386 **Figure 1. External method and matrix comparison – workflow**